Abba Zubair

Dr. Abba Zubair

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 May 2020 in Stem Cells Translational Medicine
Verified
Journal Article
Open access
PDF file
WQWenchun Qu
Wenchun Qu
ZWZhen Wang
Zhen Wang
JHJoshua M. Hare
Joshua M. Hare
GBGuojun Bu
Guojun Bu
JMJorge M. Mallea
Jorge M. Mallea
FSFred P. Sanfilippo
Fred P. Sanfilippo
Severe cases of COVID‐19 infection, often leading to death, have been associated with variants of acute respiratory distress syndrome (ARDS). Cell therapy with mesenchymal stromal cells (MSCs) is a potential treatment for COVID‐19 ARDS based on preclinical and clinical studies supporting the concept that MSCs modulate the inflammatory and remodeling processes and restore alveolo‐capillary barriers. The authors performed a systematic literature review and random‐effects meta‐analysis to determine the potential value of MSC therapy for treating COVID‐19‐infected patients with ARDS. Publications in all languages from 1990 to March 31, 2020 were reviewed, yielding 2691 studies, of which nine were included. MSCs were intravenously or intratracheally administered in 200 participants, who were followed for 14 days to 5 years. All MSCs were allogeneic from bone marrow, umbilical cord, menstrual blood, adipose tissue, or unreported sources. Combined mortality showed a favorable trend but did not reach statistical significance. No related serious adverse events were reported and mild adverse events resolved spontaneously. A trend was found of improved radiographic findings, pulmonary function (lung compliance, tidal volumes, PaO2/FiO2 ratio, alveolo‐capillary injury), and inflammatory biomarker levels. No comparisons were made between MSCs of different sources.

3 November 2020 in npj Regenerative Medicine
Verified
Journal Article
Open access
PDF file
DFDominika Fričová
Dominika Fričová
JKJennifer A. Korchak
Jennifer A. Korchak
AZAbba Zubair
Abba Zubair
Parkinson’s disease (PD) is the second most common neurodegenerative disease characterized by the progressive loss of dopaminergic neurons in the substantia nigra pars compacta and the presence of Lewy bodies, which gives rise to motor and non-motor symptoms. Unfortunately, current therapeutic strategies for PD merely treat the symptoms of the disease, only temporarily improve the patients’ quality of life, and are not sufficient for completely alleviating the symptoms. Therefore, cell-based therapies have emerged as a novel promising therapeutic approach in PD treatment. Mesenchymal stem/stromal cells (MSCs) have arisen as a leading contender for cell sources due to their regenerative and immunomodulatory capabilities, limited ethical concerns, and low risk of tumor formation. Although several studies have shown that MSCs have the potential to mitigate the neurodegenerative pathology of PD, variabilities in preclinical and clinical trials have resulted in inconsistent therapeutic outcomes. In this review, we strive to highlight the sources of variability in studies using MSCs in PD therapy, including MSC sources, the use of autologous or allogenic MSCs, dose, delivery methods, patient factors, and measures of clinical outcome. Available evidence indicates that while the use of MSCs in PD has largely been promising, conditions need to be standardized so that studies can be effectively compared with one another and experimental designs can be improved upon, such that this body of science can continue to move forward.

5 January 2010 in American Journal of Hematology
Verified
Journal Article
Closed access
PDF file
AZAbba Zubair
Abba Zubair

1 November 2020 in Cytotherapy
Verified
Journal Article
Closed access
EWElani F. Wiest
Elani F. Wiest
AZAbba Zubair
Abba Zubair

10 September 2018 in Transfusion
Verified
Journal Article
Closed access
PDF file
ARAthena L. Russell
Athena L. Russell
RLRebecca C. Lefavor
Rebecca C. Lefavor
AZAbba Zubair
Abba Zubair

1 October 2014 in Cytotherapy
Verified
Journal Article
Closed access
PHPeng Huang
Peng Huang
NGNichole Gebhart
Nichole Gebhart
ERElliott Richelson
Elliott Richelson
TBThomas G. Brott
Thomas G. Brott
JMJames F. Meschia
James F. Meschia
AZAbba Zubair
Abba Zubair